Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 10Sarcoma, Alveolar Soft Part 3Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Neoplasms 2Melanoma 2Head and Neck Neoplasms 2Gliosarcoma 2Glioblastoma 2Vulvar Neoplasms 1Urogenital Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Obesity 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lung Neoplasms 1Liposarcoma, Myxoid 1Liposarcoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1

Interventions

Nivolumab 6Imatinib Mesylate 4Ipilimumab 3Cetuximab 3pembrolizumab 2palbociclib 2Specimen Handling 2Radiotherapy 2Radiosurgery 2Protons 2Proton Therapy 2Pemetrexed 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2tazemetostat 1spartalizumab 1relatlimab 1nilotinib 1camrelizumab 1avelumab 1atezolizumab 1apatinib 1Zoledronic Acid 1X-Rays 1Tiragolumab 1Thiotepa 1Surveys and Questionnaires 1Radiotherapy, Intensity-Modulated 1Radiation 1Photochemotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chordoma × atezolizumab × Sarcoma × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡